- Latest news▼
-
16:41, April 15 Cell: in carriers of defective BRCA2 gene, sugar consumption increases cancer risk
-
15:04, April 15 305 cases of measles recorded in Armenia so far in 2024
-
14:38, April 15 Food and Environmental Virology: tea contributes to effective coronavirus control
-
12:41, April 15 Daily Mail: vitamin A, B3 and E supplements can be dangerous
-
10:56, April 15 Diabetes Care: evening physical activity is good for the heart
-
08:27, April 15 Women are more susceptible to blood loss and death during bypass surgery than men, researchers say
-
18:42, April 13 WHO: Nigeria pioneers revolutionary meningitis vaccine
-
16:43, April 13 One-third of women experience menstruation-related migraines, most often during premenopause - study
-
14:37, April 12 Pediatrics: Hypoglossal nerve stimulation implant helps with sleep apnea
-
12:13, April 12 Health minister: Simulation educational center will be created, assisted reproductive technology capacity will increase in Armenia
-
17:03, April 11 BMJ: antidepressant injection 4 times reduced risk of severe postpartum depression
-
11:35, April 11 Health minister: Number of hard-to-reach medical services within state funding scope increased in Armenia in 2023
-
16:10, April 10 Breathing therapy, which is so popular in the world, is starting to spread in Armenia
-
21:36, April 9 Frontiers: sun exposure destroys skin microbiome
-
17:24, April 9 EClinicalMedicine: depression increases the lethality of breast cancer
All materials
NSD2 is a conserved driver of metastatic prostate cancer progression
Deciphering cell-intrinsic mechanisms of metastasis progression in vivo is essential to identify novel therapeutic approaches. Here we elucidate cell-intrinsic drivers of metastatic prostate cancer progression through analyses of genetically engineered mouse models (GEMM) and correlative studies of human prostate cancer.
Expression profiling of lineage-marked cells from mouse primary tumors and metastases defines a signature of de novo metastatic progression. Cross-species master regulator analyses comparing this mouse signature with a comparable human signature identifies conserved drivers of metastatic progression with demonstrable clinical and functional relevance. In particular, nuclear receptor binding SET Domain Protein 2 (NSD2) is robustly expressed in lethal prostate cancer in humans, while its silencing inhibits metastasis of mouse allografts in vivo.
We propose that cross-species analysis can elucidate mechanisms of metastasis progression, thus providing potential additional therapeutic opportunities for treatment of lethal prostate cancer.
Full article: Nature Communications.
Follow NEWS.am Medicine on Facebook and Twitter
- Video
- Event calendar
- Archive
- Most read
month
week
day
- Breathing therapy, which is so popular in the world, is starting to spread in Armenia 1781
- Frontiers: sun exposure destroys skin microbiome 1336
- EClinicalMedicine: depression increases the lethality of breast cancer 1335
- FEV: Black tea inactivates SARS-CoV-2 in saliva 1333
- BMJ: antidepressant injection 4 times reduced risk of severe postpartum depression 1105
- Health minister: Number of hard-to-reach medical services within state funding scope increased in Armenia in 2023 1066
- Pediatrics: Hypoglossal nerve stimulation implant helps with sleep apnea 966
- Health minister: Simulation educational center will be created, assisted reproductive technology capacity will increase in Armenia 930
- WHO: Nigeria pioneers revolutionary meningitis vaccine 763
- One-third of women experience menstruation-related migraines, most often during premenopause - study 743
- Women are more susceptible to blood loss and death during bypass surgery than men, researchers say 399
- Food and Environmental Virology: tea contributes to effective coronavirus control 383
- Daily Mail: vitamin A, B3 and E supplements can be dangerous 378
- Diabetes Care: evening physical activity is good for the heart 350
- 305 cases of measles recorded in Armenia so far in 2024 330
- Find us on Facebook
- Poll